

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **PEPE FRANCESCA FULVIA**
Working Address **VIA G.B. PERGOLESÌ 33, MONZA (MB), 20900, ITALY**
Mobile
Fax
E-mail **francescafulvia.pepe@irccs-sangerardo.it**
Nationality **ITALIAN**

WORK EXPERIENCE

- Dates 06/09/2021 – present
• Name and address of the employer Fondazione IRCCS San Gerardo dei Tintori, via G.B. Pergolesi, 33, MONZA
• Type of business or sector Phase 1 Research Centre
• Occupation or position held Medical Doctor - Oncologist
• Main activities and responsibilities Clinical activity – Clinical Research Trials.
I've been involved in several clinical trials according to ICH GCP. Last GCP training performed on 01/09/2020 (ICH/GCP HCPs V2.1)
- Dates 12/11/2020 – 05/09/2021
• Name and address of the employer Ospedale San Gerardo ASST-Monza, via G.B. Pergolesi, 33, MONZA
• Type of business or sector Oncology Department
• Occupation or position held Medical Doctor - Oncologist
• Main activities and responsibilities Clinical activity – Clinical Research Trials
I've been involved in several clinical trials according to ICH GCP. Last GCP training performed on 01/09/2020 (ICH/GCP HCPs V2.1)

EDUCATION AND TRAINING

- Dates 01/11/2015 – 31/10/2020
• Name and type of organisation providing education and training Università degli Studi di Milano Statale – Università Milano Bicocca
• Principal subjects/occupational skills covered Resident Doctor: Day Hospital activity in breast cancer – lung cancer – gastrointestinal&bilipancreatic cancer – skin cancer – genitourinary cancer – sarcomas
• Title of qualification awarded Onco-specialist (70/70 cum laude)
- Dates 11/2007 – 03/2015
• Name and type of organisation providing education and training Università degli Studi di Bari "Aldo Moro" – Faculty of Medicine
• Principal subjects/occupational skills covered Medical Student
• Title of qualification awarded Degree in Medicine & Surgery (110/110 cum laude)
- Dates 01/2014 – 09/2014

- Name and type of organisation providing education and training
Université de Strasbourg – Faculté de Médecine
 - Principal subjects/occupational skills covered
Medical Student (ERASMUS project) – internship in Orthopedics, Neurology, Gynecology and Clinical Pharmacology
-
- Dates
09/2002 – 06/2007
 - Name and type of organisation providing education and training
Liceo Classico "Quinto Orazio Flacco" di Bari
 - Principal subjects/occupational skills covered
Student especially in cultural heritage conservation
 - Title of qualification awarded
Secondary high school degree (90/100)
-
- Dates
09/2002 – 06/2006
 - Name and type of organisation providing education and training
Conservatorio di Musica "Niccolò Piccini" di Bari
 - Principal subjects/occupational skills covered
Violin player - Solfeggio
 - Title of qualification awarded
Solfeggio degree (9.5/10)

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE **ITALIAN**

OTHER LANGUAGES

- Understanding **ENGLISH**
excellent
- Speaking good
- Writing good

- Understanding **FRENCH**
- Speaking B1
- Writing B1

SOCIAL SKILLS AND COMPETENCES Ability to work both independently and as part of a team.
Soft skills, Problem solving, team work skills.

TECHNICAL SKILLS AND COMPETENCES Microsoft Office
PC Operation Systems: Windows, MacOSX

OTHER SKILLS AND COMPETENCES SPORT: SWIM – JUDO

DRIVING LICENCE(S)

B

PUBLICATIONS

Pepe FF, Cazzaniga ME, Baroni S, Riva F, Cicchiello F, Capici S, Cogliati V, Maggioni C, Cordani N, Cerrito MG, Malandrini S.

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study. BMC Cancer. 2022 Sep 6;22(1):956. doi: 10.1186/s12885-022-10031-6. PMID: 36068484; PMCID: PMC9446532.

Cogliati V, Capici S, Pepe FF, di Mauro P, Riva F, Cicchiello F, Maggioni C, Cordani N, Cerrito MG, Cazzaniga ME.

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life (Basel). 2022 Mar 5;12(3):378. doi: 10.3390/life12030378. PMID: 35330128; PMCID: PMC8954717.

Cazzaniga ME, Capici S, Cordani N, Cogliati V, Pepe FF, Riva F, Cerrito MG.

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows. J Clin Med. 2022 Aug 12;11(16):4710. doi: 10.3390/jcm11164710. PMID: 36012949; PMCID: PMC9410269.

Capici S, Ammoni LC, Meli N, Cogliati V, Pepe FF, Piazza F, Cazzaniga ME.

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. Cancers (Basel). 2022 Jul 31;14(15):3729. doi: 10.3390/cancers14153729. PMID: 35954393; PMCID: PMC9367432.

Pierluigi di Mauro, Serena Capici, Viola Cogliati, Francesca Fulvia Pepe, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga,

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report, Current Problems in Cancer: Case Reports, Volume 6, 2022, 100167, ISSN 2666-6219, <https://doi.org/10.1016/j.cpcr.2022.100167>.

Meazza Prina Marco, Gotuzz Irene, Cazzaniga Marina, De Bernardi Elisabetta, Cafaro Pietro, Capici Serena, Cogliati Viola, Pepe Francesca, et Al. Guerra Luca. (2023). Abstract P6-01-42: Baseline 18FDG-PET metabolic tumour volume (MTV) as a potential predictive factor of response to metronomic chemotherapy (mCHT) in HR+/HER2- metastatic breast cancer (MBC) patients (pts). Preliminary results of the metro-PET study. Cancer Research. 83. P6-01. 10.1158/1538-7445.SABCS22-P6-01-42.

Cordani Nicoletta, Mogni Luca, Piazza Rocco, Cogliati Viola, Pepe Francesca, Capici Serena, Di Bella Camillo, Jaconi Marta, Cerrito Maria Grazia, Villa Matteo, Tettamanti Pietro, Cavaletti, Guido, Lavitrano Marialuisa, Cazzaniga Marina. (2023). Abstract P1-13-21: Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells. Cancer Research. 83. P1-13. 10.1158/1538-7445.SABCS22-P1-13-21.

I authorize the processing of personal data contained in my curriculum vitae according to art. 13 of Legislative Decree 196/2003 and art. 13 GDPR 679/16

MONZA, 12/06/2023

Francesca Fulvia Pepe